Voyager Therapeutics, Inc. · NASDAQ:VYGR
Voyager Therapeutics — ASGCT 28th Annual Meeting (May 2025)
22 slides from Voyager Therapeutics's conference presentation, May 14, 2025
Slide 1: Discovery of AAV9-derived CNS capsids evading pre-existing neutralizing antibodies
Discovery of AAV9-derived CNS capsids evading pre-existing neutralizing antibodies Damien Maura, Ph.D Senior Scientist II, Novel Capsid Discovery ASGCT 28th Annual meeting AAV Gene Transfer (A): Crossing the Blood-Brain Barrier Wednesday May 14th, 2025 CO N F I D E N T I AL
Slide 2: Disclosures
Disclosures • Damien Maura is a full-time employee of Voyager Therapeutics |2|
Slide 3: Leveraging TRACER platform to de-immunize Voyager's CNS capsids
Leveraging TRACER platform to de-immunize Voyager’s CNS capsids and increase patient eligibility for AAV gene therapy
Slide 4: Development of a mouse passive immunization model with human IVIG
Development of a mouse passive immunization model with human IVIG
Slide 5: Screen for IVIG-evading variants that retain brain transduction in mouse
Screen for IVIG-evading variants that retain brain transduction in mouse
Slide 6: Screen for IVIG-evading variants that retain brain transduction in mouse
Screen for IVIG-evading variants that retain brain transduction in mouse
Slide 7: VCAP-Gen2-A1 evades human neutralizing antibodies and retains brain transduction in mouse
VCAP-Gen2-A1 evades human neutralizing antibodies and retains brain transduction in mouse
Slide 8: VCAP-Gen2-A1 evades human neutralizing antibodies and retains brain transduction in mouse
VCAP-Gen2-A1 evades human neutralizing antibodies and retains brain transduction in mouse
Slide 9: VCAP-Gen2-A1 evades human neutralizing antibodies and retains brain transduction in mouse
VCAP-Gen2-A1 evades human neutralizing antibodies and retains brain transduction in mouse
Slide 10: VCAP-Gen2-A1-B1 further evades human antibodies with minimal impact on brain transduction
VCAP-Gen2-A1-B1 further evades human antibodies with minimal impact on brain transduction
Slide 11: Evaluation of VCAP-Gen2-A1 & VCAP-Gen2-A1-B1 in NHP
Evaluation of VCAP-Gen2-A1 & VCAP-Gen2-A1-B1 in NHP
Slide 12: VCAP-Gen2-A1 transduces NHP brain in an animal with pre-existing antibodies
VCAP-Gen2-A1 transduces NHP brain in an animal with pre-existing antibodies
Slide 13: VCAP-Gen2-A1 transduces NHP brain in an animal with pre-existing antibodies
VCAP-Gen2-A1 transduces NHP brain in an animal with pre-existing antibodies
Slide 14: VCAP-Gen2-A1 transduces NHP brain in an animal with pre-existing antibodies
VCAP-Gen2-A1 transduces NHP brain in an animal with pre-existing antibodies
Slide 15: VCAP-Gen2-A1 transduces NHP brain in an animal with pre-existing antibodies
VCAP-Gen2-A1 transduces NHP brain in an animal with pre-existing antibodies
Slide 16: VCAP-Gen2-A1 retains brain cellular tropism of its parent VCAP-Gen2
VCAP-Gen2-A1 retains brain cellular tropism of its parent VCAP-Gen2
Slide 17: Leveraging machine learning to identify improved mutations in region B
Leveraging machine learning to identify improved mutations in region B
Slide 18: Leveraging machine learning to identify improved mutations in region B
Leveraging machine learning to identify improved mutations in region B
Slide 19: Top ML candidates for region B are improved for both NAb evasion and brain transduction in mouse
Top ML candidates for region B are improved for both NAb evasion and brain transduction in mouse
Slide 20: Summary
Summary voyager VCAP-Gen2-A1 is a 3™ generation TRACER AAV capsid with a combination of high brain transduction and antibody evasion = = = = => . VCAP-Gen2-A1 could allow 40% more patients to receive AAV gene therapy yy» * VCAP-Gen2-A1 transduces NHP brain in the presence of natural pre-existing NAb
Slide 21: Acknowledgments
Acknowledgments Novel Capsid Discovery team: Neuroscience team: Vector Production Team: * Mathieu Nonnenmacher * Charlotte Chung * Kyle Grant + Jennifer Yu * Michael Grannan * Timothy Fiore * Xiaoqgin Ren * Roberto Calitri * Dillon Kavanagh * Matt Child * Ambreen Sayed-Zahid Rupinderjit Kaur Maneesh
Slide 22: Questions?
Questions? voyager therapeutics
Voyager Therapeutics — ASGCT 28th Annual Meeting (May 2025) on 6ix